Sign inJoin waitlistJoin the waitlist

Douglas A Tremblay

Hematology · Icahn School of Medicine at Mount Sinai

Credentials: · · ·

History

Research

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Review · Haematologica · 2016 · 149 citations
Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study
Journal of Medical Virology · 2021 · Last of 7 authors · 78 citations
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
Thrombosis Research · 2020 · Last of 19 authors · 78 citations

John Mascarenhas
84 papers
Leonard Naymagon
25 papers · 1 as a fellow
Ronald Hoffman
23 papers
Jonathan Feld
22 papers
Marina Kremyanskaya
20 papers
Thomas Schiano
17 papers
DS
Dahniel Sastow
13 papers · 13 as a resident
Ruben Mesa
12 papers
Sheena Bhalla
12 papers · 12 as a resident
Alexander Coltoff
10 papers · 8 as a fellow
Bridget Marcellino
9 papers
GL
Guido Lancman
7 papers · 7 as a resident

Clinical trials

Imetelstat Combinations in Relapsed AML
Principal investigator · Recruiting · Phase 1
Douglas Tremblay
2026–2035
Pacritinib in CMML
Principal investigator · Recruiting · Phase 1, Phase 2
Douglas Tremblay
2024–2028
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027